Educated in Business Studies and Marketing, Rob has spent over 30 years’ profitably building multinational and early stage businesses within Pharmaceutical, Medical Devices, Diagnostic and Consumer Healthcare market sector. Read More »
Having previously held senior management/director roles with leading companies (including RPR, Pharmacia and Unilever), Rob founded Roboleo & Co in 2004 with the specific focus on commercialisation of innovative technologies. Over the years he led the development of the company to create one of the first specialist Market Access consultancies and has built a strong team of thought leaders to ensure they consistently deliver innovative, bespoke solutions - and have the track-record to prove it.
Iain has been a partner with Roboleo since 2008 and has worked in the Pharmaceutical Industry for over 30 years. His early career was spent in the UK working with Merck before moving to GSK, where he held a number of senior roles in Sales and Marketing. He has also spent time working throughout Europe, delivering client projects in different therapeutic areas. Read More »
Since leaving GSK, he has worked as a consultant and during his time at Roboleo has helped develop the company’s Health Economics and HTA franchise. He currently works with existing and new clients advising on HTA strategies and working with our internal teams of experts to ensure seamless delivery of projects.
Iain is also responsible for setting up and managing Roboleo’s Health Economics training which has been hugely successful and is now a familiar event in the calender, having been attended by many industry professionals over the last 8 years.
Chris is Chair in Health Economics (specialising in HTA) at the University of Leeds. He is an empirical health economist specialising in the analysis of observational datasets and their role in HTA. He combines a technical expertise with an ability to understand the bigger picture, specifically where and how new technologies can demonstrate their economic argument, early identification of the challenges of demonstrating that argument and knowing which elements of an argument to enhance and those which should be avoided within an economic evaluation framework. Read More »
Previous positions include Senior Research Fellow at the Centre of Health Economics (CHE) at the University of York and a director of a leading international health economic consultancy.
He joined Roboleo & Co in 2009.
Nils is a Senior Research Fellow in the Health Policy Team. He joined the Centre for Health Economics in 2009. He holds a PhD in Economics and a MSc in Health Economics, both from the University of York, and a BSc in Health Care Management from the University of Duisburg-Essen, Germany. Read More »
He has been a consultant to Roboleo & Co since 2015 and has worked on a wide of variety of strategic projects, HTA submissions and modelling projects. Nils’ research focuses on unwarranted variation in health care provision, performance assessment of health care providers, measurement of health care quality using patient-reported outcome measures (PROMs), and the cost-effectiveness of (non-)financial incentives.
In addition to her work at Roboleo Louise has over eight years’ experience as an academic researcher at the University of Exeter Medical School specialising in health technology assessment and health economics, as well as experience of using evidence synthesis and budget impact modelling in local decision making in a clinical commissioning group (CCG). Read More »
The majority of my academic experience has been as a health technology assessment analyst for the Peninsula Technology Assessment Group (PenTAG), one of 10 teams conducting research to support the work of the UK National Institute for Health and Care Excellence (NICE) HTA programme. This included systematic reviews of diagnostic test accuracy, systematic reviews of clinical and cost effectiveness, and the critique and development of de novo health economic models.
In addition, she has experience of using evidence synthesis in the local decision-making process through her role as Clinical Evidence Scientist at the North East and West (NEW) Devon CCG, conducting rapid reviews of both interventions (without NICE guidance), surgical procedures to summarise available clinical and cost-effectiveness evidence as well as conducting budget impact analyses.
Louise’s consultancy experience includes:
Louise holds an MSc in Health Economics and Health Policy from the University of Birmingham (2014), and a BA in English Language and Literature from the University of Swansea.
Tracey has been involved in systematic reviews and health technology assessments at the University of Exeter for over 7 years, followed by 2 years as a senior research associate within a health economic and outcomes research consultancy. She is an experienced Medical Writer and joined Roboleo & Co in 2019 to work on a variety of client projects.
Harriet has over 10 years’ experience working in academic health research at the University of Exeter Medical School, specialising in diagnostics, test evaluation and evidence synthesis. She has authored a large number of evidence reports including reviews of diagnostic test accuracy, prognostic evaluation and medical technologies. Read More »
With a keen interest in generating evidence and translating complex information for a range of customers, Harriet has extensive experience in creative communication and visual thinking for health research audiences.
She has contributed to several international methods development groups for diagnostic evaluation and has authored NICE-commissioned reviews under their Public Health programme as well as having published in the BMJ, JAMA and JRSM.
Mark is a medically-qualified and highly experienced drug developer with 20 years' pharmaceutical R&D experience. He has worked at all phases of clinical drug development across a wide variety of therapeutic areas, including orphan diseases. He was a Global Clinical R&D Director and then Director of Science and Medical Public Affairs at Pfizer in Sandwich. Earlier in his career he was an NHS anaesthetist and intensive care doctor. Read More »
He has also significant experience at the R&D interfaces between academia, the NHS and the biopharmaceutical industry e.g. having helped lead the establishment of the MRC/industry pre-competitive consortia in COPD and RA and the UK Government's Translational Research Partnership Programme.
Mark has been a Medical Advisor to Roboleo & Co since 2011 and provides 'hands-on' clinical, scientific and policy leadership to small and medium-sized pharmaceutical companies. He is currently Director of the South West Academic Health Science Network.